{"id":"W3008798432","doi":"10.1016/j.ejca.2020.01.008","title":"European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment","year":2020,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":320,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Janssen Canada; Janssen Pharmaceuticals; Merck Sharp and Dohme; NeraCare; Sun Pharma; Universidad de Cantabria; ZonMw; Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares; Vertex Pharmaceuticals; Mylan; Regeneron Pharmaceuticals; Eisai Korea; Agence Nationale de la Recherche; F. Hoffmann-La Roche; Millennium Challenge Corporation; Università Degli Studi di Modena e Reggio Emila; Immunocore; Novartis Pharma; AbbVie; Novartis; Celgene; Pfizer; Biogen; Arthrex GmbH; LEO Pharma; LEO Pharma Research Foundation; Wyeth; Janssen Biotech; Les Laboratories Pierre Fabre; Meso Scale Diagnostics; Sanofi; Roche; Merck; GlaxoSmithKline; AstraZeneca; Eli Lilly and Company; Leo Baeck Institute; Bristol-Myers Squibb; Amgen; Meadows Foundation; EMD Serono; Almirall; Galderma; BioNTech","keywords":"Medicine; Cetuximab; Systemic therapy; Radiation therapy; Guideline; Oncology; Lymph node; Internal medicine; Cancer; Dissection (medical); Surgery; Pathology; Colorectal cancer; Breast cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003512881,0.0002308159,0.0004551319,0.00005941627,0.00008422104,0.00001092751,0.000320267,0.00001292013,0.000183184],"category_scores_gemma":[0.0001008694,0.0001332387,0.0003573622,0.0001716808,0.0001253946,0.00004528707,0.0002879145,0.0002752641,0.00004451131],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002143526,"about_ca_system_score_gemma":0.0002152213,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007311326,"about_ca_topic_score_gemma":0.00001115193,"domain_scores_codex":[0.9978811,0.0004376328,0.0008593399,0.0002100057,0.0004152512,0.0001966606],"domain_scores_gemma":[0.9983578,0.00007569108,0.0007548381,0.0003176259,0.0002958809,0.0001981148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"observational","study_design_scores_codex":[0.006065994,0.00119439,0.1623578,0.0005377994,0.001015845,0.008326916,0.03795807,0.001897956,0.01218768,0.00002371214,0.6836668,0.08476707],"study_design_scores_gemma":[0.01091052,0.01397888,0.5384039,0.0009024143,0.0008845864,0.0002849489,0.002241658,0.00002508109,0.0873372,0.000008812999,0.3446452,0.0003767991],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.862914,0.007859004,0.00004260435,0.02372936,0.001024104,0.0003008053,0.00004010168,0.00001143912,0.1040786],"genre_scores_gemma":[0.9935687,0.0003112041,0.0001706699,0.002504922,0.002454275,0.000001628891,0.000001526337,0.00006798292,0.0009190491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3760461,"threshold_uncertainty_score":0.5433316,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03598642157108808,"score_gpt":0.2937085446046721,"score_spread":0.257722123033584,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}